Bicara Therapeutics Inc has a consensus price target of $41 based on the ratings of 4 analysts. The high is $47 issued by Stifel on October 8, 2024. The low is $35 issued by Morgan Stanley on October 8, 2024. The 2 most-recent analyst ratings were released by Stifel and Morgan Stanley on October 8, 2024, respectively. With an average price target of $41 between Stifel and Morgan Stanley, there's an implied 64.63% upside for Bicara Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Bicara Therapeutics (NASDAQ:BCAX) was reported by Cantor Fitzgerald on October 8, 2024. The analyst firm set a price target for $0.00 expecting BCAX to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Bicara Therapeutics (NASDAQ:BCAX) was provided by Cantor Fitzgerald, and Bicara Therapeutics initiated their overweight rating.
There is no last upgrade for Bicara Therapeutics
There is no last downgrade for Bicara Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bicara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bicara Therapeutics was filed on October 8, 2024 so you should expect the next rating to be made available sometime around October 8, 2025.
While ratings are subjective and will change, the latest Bicara Therapeutics (BCAX) rating was a initiated with a price target of $0.00 to $0.00. The current price Bicara Therapeutics (BCAX) is trading at is $23.20, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.